

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Makoto KAIBARA et al.

Group Art Unit : 1614

Appln. No : 10/733,288

Examiner : Unknown

Filed : December 12, 2003

For : BLOOD COAGULATION FACTOR-ACTIVATING PROTEIN AND ANTIBODY  
THERE TO

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir :

In accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. 1.98(d).

Applicants hereby make of record the disclosure statement filed August 20, 2001 and further document submitted with the Amendment filed April 14, 2003, and the information cited by the Examiner in the Office Action mailed December 13, 2002 in parent Application No. 09/861,708.

Applicants also bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in an European Search Report issued in connection with counterpart European Application No. 01 11 2430. A copy of the European Search Report (in English) is enclosed herewith. The Examiner is invited to review these materials to inspect the relevance indicated during European examination with respect to the documents cited therein.

WO 00/17658;

WO 97/47737;

Kenneth A. BAUER et al., "Factor IX is Activated In VIVO by the Tissue Factor Mechanism", Blood, Vol. 76, No. 4, pp. 731-736 (1990);

S. KAWAKAMI et al., "Rheological Approach to the Analysis of Blood Coagulation in Endothelial Cell-Coated Tubes: Activation of the Intrinsic Reaction on the Erythrocyte Surface", Biorheology, Vol. 32, No. 5, pp. 521-536 (1995);

G. SARKAR et al., "Direct Sequencing of the Activation Peptide and the Catalytic Domain of the Factor IX Gene in Six Species", Genomics, Vol. 6, pp. 133-143 (1990);

Masahiro YAMAMOTO, "Effects of Fibrinogen, Globulin, Albumin and Hematocrit on the Kinetics of Erythrocyte Aggregation in Man", Angiology, Vol. 37, No. 9, pp. 663-671 (1986); and

M. KAIBARA et al., "S22-1 Factor IX Activation by Erythrocyte Membranes is a Powerful Trigger for Thrombus Formation Under Stagnant Flow Conditions", Biorheology, Vol. 39, No. 5, pp. 654 (2002).

Applicants note that the European Search Report lists U.S. Patent Nos. 6,277,618 and 6,342,585 as family members of WO 97/477,737.

Applicants note that copies of documents cited in the parent Application No. 09/861,708 are included in the parent application. Accordingly, pursuant to 37 C.F.R. 1.98(d) copies of the documents are not being submitted herewith, and the Examiner is invited to review and consider the documents in the parent application. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.


Copies of the newly cited documents are enclosed together with a duly completed Form PTO-1449 listing each of the previously-cited and newly-cited documents. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. 1.98 (a)(2)(i), copies of the U.S. patents and U.S. published patent applications are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.


In accordance with 37 C.F.R. 1.97(b)(1), this Information Disclosure Statement is filed within three months of the filing date of the application. Accordingly, no fees are required.


Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully submitted,  
Makoto KAIBARA et al.

  
\_\_\_\_\_  
Bruce H. Bernstein  
Reg. No. 29,027

March 11, 2004  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P24684		Serial No. 10/733,288	
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>				Applicant Makoto KAIBARA et al.			
				Filing Date December 12, 2003		Group 1614	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5 1 8 0 8 1 9	01/1993	CAYRE			
		5 9 6 8 7 8 2	10/1999	STEVENS			
		6 2 3 2 4 5 6	05/2001	COHEN et al.			
		6 2 7 7 6 1 8	08/21/01	KOPETZKI et al.			
		6 3 4 2 5 8 5	01/29/02	GROSSMANN			
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		0 0 / 1 7 6 5 8	03/30/00	W.I.P.O.			
		9 7 / 4 7 7 3 7	12/18/97	W.I.P.O.			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	1	KAWAKAMI et al., <u>Biorheology</u> , Vol. 32, No. 5, pp. 521-536 (1995).					
	2	KAIBARA et al., Frontier Research on Circulation System Dynamics (report on research performed under a grant from the Science and Technology Agency, 1998), edited by Okayama New Technology Promotion Foundation, pp. 43-54 (1999).					
	3	KÖHLER et al., <u>Nature</u> , Vol. 256, pp. 495-497 (1975).					
	4	MASUTANI et al., <u>Nature</u> , Vol. 399, No. 6737, pp. 700-704 (1999).					
	5	KAIBARA et al., <u>Biorheology</u> , Vol. 22, No. 3, pp. 197-208 (1985).					
	6	KAIBARA et al., <u>Colloids and Surfaces B: Biointerfaces</u> , 19, pp. 209-217 (2000).					
	7	SAKAMOTO et al., <u>Medical Engineering and Bioengineering</u> , Vol. 16, pp. 45-52 (1978)					
	8	FUJII et al., <u>47th Rheology Forum Abstracts</u> , pp. 295-296 (1999).					
	9	ANDERSSSEN et al., <u>Thrombosis and Haemostasis</u> , 70, (3), pp. 414-417 (1993).					
	1 0	KAWAMATA et al., <u>Intensive Care Med.</u> , 21, pp. 443-446 (1995).					
	1 1	NAKAMURA et al., "Protein Structure", <u>Molecular Biology of the Cell</u> , No. 1, pp. 111-127 (1985).					
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P24684		Serial No. 10/733,288	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (See several sheets if necessary)				Applicant Makoto KAIBARA et al.			
				Filing Date December 12, 2003		Group 1614	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS TRANSLATION YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	1	2	ERNST, <u>Journal des Maladies Vasculaires</u> , 17, pp. 93-96 (1992).				
	1	3	MAMMEN, <u>Chest</u> , 102, 6, pp. 640S-644S (1992).				
	1	4	CHIEN, <u>Science</u> , Vol. 168, pp. 977-979 (1970).				
	1	5	YASAKA et al., <u>J. Heart Valve Dis.</u> , Vol. 2, pp. 25-34 (1993).				
	1	6	KAIBARA et al., <u>Am. J. Obstet. Gynecol.</u> , Vol. 180, No. 2, Part 1, pp. 402-405 (1999).				
	1	7	LUPU et al., <u>Thrombosis and Haemostasis</u> , 70, (4), pp. 579-583 (1993).				
	1	8	Narayanam V. RAO et al., "Characterization of Proteinase-3 (PR-3), a Neutrophil Serine Proteinase", <u>The Journal of Biological Chemistry</u> , Vol. 266, No. 15, pp. 9540-9548 (1991).				
	1	9	Imamura et al. <u>Biochem J.</u> , (2001) 353:325-331.				
	2	0	Kenneth A. BAUER et al., "Factor IX is Activated In VIVO by the Tissue Factor Mechanism", <u>Blood</u> , Vol. 76, No. 4, pp. 731-736 (1990).				
	2	1	S. KAWAKAMI et al., "Rheological Approach to the Analysis of Blood Coagulation in Endothelial Cell-Coated Tubes: Activation of the Intrinsic Reaction on the Erythrocyte Surface", <u>Biorheology</u> , Vol. 32, No. 5, pp. 521-536 (1995).				
	2	2	G. SARKAR et al., "Direct Sequencing of the Activation Peptide and the Catalytic Domain of the Factor IX Gene in Six Species", <u>Genomics</u> , Vol. 6, pp. 133-143 (1990).				
	2	3	Masahiro YAMAMOTO, "Effects of Fibrinogen, Globulin, Albumin and Hematocrit on the Kinetics of Erythrocyte Aggregation in Man", <u>Angiology</u> , Vol. 37, No. 9, pp. 663-671 (1986).				
	2	4	M. KAIBARA et al., "S22-I Factor IX Activation by Erythrocyte Membranes is a Powerful Trigger for Thrombus Formation Under Stagnant Flow Conditions", <u>Biorheology</u> , Vol. 39, No. 5, pp. 654 (2002).				
EXAMINER		DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							